pancreatic mass pancreatic mass
Conditions
Interventions
Patients with pancreatic masses will be randomly assigned in a 1:1 ratio to undergo endoscopic ultrasound-guided tissue acquisition (EUS-TA) using either a dual-beveled raptor tip needle or a Franseen
D004717, D001982
endoscopic ultrasound-guided tissue acquisition, EUS-TA, dual-beveled raptor tip needle
Sponsors
Murabayashi Toji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with pancreatic masses identified on imaging studies (CT, MRI, abdominal ultrasonography, or endoscopic ultrasonography) who are scheduled to undergo endoscopic ultrasound-guided tissue acquisition (EUS-TA).
Exclusion criteria
Exclusion criteria: 1. Patients with a prior pathological diagnosis of pancreatic cancer who undergo endoscopic ultrasound-guided EUS-TA solely for the purpose of comprehensive cancer genomic profiling. 2. Inability to visualize the pancreatic mass by endoscopic ultrasonography due to anatomical reasons. 3. Lesions deemed not amenable to needle puncture based on imaging studies. 4. Bleeding tendency, defined as a prothrombin time-international normalized ratio (PT-INR) > 1.5 or a platelet count < 50000/mm3. 5. Inability to discontinue two or more antithrombotic agents. 6. Age < 18 years. 7. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological diagnostic accuracy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Technical success rate 2. Difficulty of needle puncture 3. Procedure-related adverse events 4. Macroscopic quantity and quality of the obtained specimen 5. Histological tissue quantity 6. Histological tumor tissue quantity | — |
Contacts
Public ContactToji Murabayashi
Ise Red Cross Hospital
Outcome results
None listed